| Literature DB >> 30782045 |
Magdalena A Karaś1, Anna Turska-Szewczuk1, Monika Janczarek1, Agnieszka Szuster-Ciesielska2.
Abstract
Innate immunity is an evolutionarily ancient form of host defense that serves to limit infection. The invading microorganisms are detected by the innate immune system through germline-encoded PRRs. Different classes of PRRs, including TLRs and cytoplasmic receptors, recognize distinct microbial components known collectively as PAMPs. Ligation of PAMPs with receptors triggers intracellular signaling cascades, activating defense mechanisms. Despite the fact that Gram-negative bacteria and parasitic protozoa are phylogenetically distant organisms, they express glycoconjugates, namely bacterial LPS and protozoan GPI-anchored glycolipids, which share many structural and functional similarities. By activating/deactivating MAPK signaling and NF-κB, these ligands trigger general pro-/anti-inflammatory responses depending on the related patterns. They also use conservative strategies to subvert cell-autonomous defense systems of specialized immune cells. Signals triggered by Gram-negative bacteria and parasitic protozoa can interfere with host homeostasis and, depending on the type of microorganism, lead to hypersensitivity or silencing of the immune response. Activation of professional immune cells, through a ligand which triggers the opposite effect (antagonist versus agonist) appears to be a promising solution to restoring the immune balance.Entities:
Keywords: Glycolipids of protozoa; LPS; PAMPs; homeostasis; innate immunity
Mesh:
Substances:
Year: 2019 PMID: 30782045 PMCID: PMC6830889 DOI: 10.1177/1753425918821168
Source DB: PubMed Journal: Innate Immun ISSN: 1753-4259 Impact factor: 2.680
Figure 1.Main TLR-mediated signaling pathways triggered upon stimulation by LPS and LPG. Downstream of TLR4 and TLR2 receptors, both LPS and LPG can generate signals through a common MyD88-dependent pathway, while a MyD88-independent pathway is peculiar to TLR4 signaling. The activation of the canonical pathway results in early phase activation of the NF-κB factor and production of inflammatory cytokines. By contrast, signaling through the non-canonical pathway leads to late phase transformation of inactive NF-κB to an active form and production of type I IFNs. In primed Mϕs, both LPS and LPG can be sensed through NLRP3 inflammasome. Excessive immune response, which can be detrimental to the host, is regulated by negative feedback. The main role in the regulation of TLR2/4 signaling, and, hence, the production of IL-12 and excessive Th1 polarization, is played by the endogenous suppressors PI3Ks. The activation of the PI3K/Akt/mTOR pathway by both LPS and LPG results in the production of anti-inflammatory cytokines. Negative regulation of TLR2 and TLR 4 signaling also involves other suppressor molecules. For more details, see text.
Published studies evaluating the effect of TLRs stimulation by the investigated ligands.
| Ligand/organism | Receptor | Tested system (Model) | Disease | Outcome | References |
|---|---|---|---|---|---|
|
| |||||
| TLR4 | C3H/OuJ miceMϕs | Non-infectious | ↑ IL-1β, IL-12, IL-6, MIP-1α, MIP-2, MCP-5, IP-10, TNF-α, IFN-γ | Hirschfeld et al.[ | |
|
| |||||
| Synthetic lipid A analog 506 [14:0, 16:0, 2 x 14:0(3-OH)][ | TLR4 | hPBMC | Non-infectious | IL-8, TNF-α production | Tamai et al.[ |
| Synthetic lipid A analog 406 [4 x 14:0(3-OH)][ | TLR4 | hPBMC | Non-infectious | no IL-8, TNF-α | Tamai et al.[ |
|
| |||||
| TLR4TLR2/? | C57BL/6 miceIFN-γ primed Mϕs | ML | ↑ TNF-α, IL-1β, IL-6, NO↓ IL-10, IL-12, IFN-γ, IL-2, IL-4, IL-5 | Paranaíba et al.[ | |
| TLR4 | C57BL/6 miceIFN-γ primed Mϕs | CL | ↑ TNF-α, IL-6, NO↓ IL-1β, IL-10 and IL-12;no activation of NF-κB | Nogueira et al.[ | |
| TLR2/TLR1 | C57BL/6 miceIFN-γ primed Mϕs | VL | the release of PGE2, MCP-1↑ IL-6, TNF-α, IL-12, ↓ IL-10, | Lima et al.[ | |
| TLR2/?TLR4 | C57BL/6 miceIFN-γ –primed Mϕs | Non-infectious | production of NO, IL-6, IL-12 and TNF–α, no activation of NF-κB | Paranaíba et al.[ | |
| BALB/c miceMϕs | CL | production IL-10no IL-12, TNF-α | Passero et al.[ | ||
|
| TLR2/? | RAW-ELAM Mϕs | CL | TNF-α, IFN-γ productionNF-κB activation | De Veer et al.[ |
| TLR4 and TLR2/? | hMϕsDCs | CL | TNF-α, IL-1β, IL-12, IL-10 productionTNF-α, IL-12 production, NF-κB activationno IL-10 | Rojas-Bernabé et al.[ | |
|
| |||||
|
| TLR2/? | RAW-ELAM Mϕs | CL | No activation of NF-κB and TNF-α production | De Veer et al.[ |
| BALB/c miceMϕs | CL | IL-12, IL-10, TNF-α, NO production | Passero et al.[ | ||
| TLR2/? | C57BL/6 miceIFN-γ –primed Mϕs | Non-infectious | NO, IL-6, IL-12, TNF–α production, NF-κB activation | Paranaíba et al.[ | |
| TLR4 | C57BL/6 miceMϕsBALB/c miceMϕs | VLCL | TNF–α, NO productionInhibition IL1-β, IL-2, IL-4, IL-5, IL-10, IL-12, IFN-γ, As above, no NO production | Assis et al.[ | |
| TLR4 | C57BL/6 miceMϕsBALB/c miceMϕs | VLCL | Inhibition of IL1-β, IL-2, IL-4, IL-5, IL-10, IL-12, IFN-γ TNF–α, NO productionas above, no NO production | Assis et al.[ | |
|
| LPS-primed MϕsLPS-primed DCs | ChD | Inhibition of TNF-α, IL-10, IL-12 | Brodskyn et al.[ | |
|
| |||||
| Free GPIs | TLR2/TLR1 | Mϕsline 264.7, J774.1 | M | Induction of production of TNF-α, IL-1, IL-6, IL-12, IFN-γ, NO | Krishnegowda et al.[ |
| tGPI-mucin | TLR2/? | C3H/HeJ C3H/HeN miceIFN-γ primed Mϕs | ChD | NO, IL-12, TNF-α production | Dos-Santos et al.,[ |
Abbreviations: hPBMC – human peripheral blood mononuclear cells, hMϕs – human Mϕs, ML – mucosal leishamaniasis, CL – mucocutaneous leishamaniasis, VL – visceral leishmaniasis, ChD – Chagase disease.
aCompound 506 is a monosaccharide analog of E. coli lipid A, while compound 406 is monosaccharide analog of biosynthetic precursor of disaccharide E. coli lipid A.